The equity investment is part of a cancer vaccine development deal between the companies that could eventually reach more than $1.7bn in size.

The cash will allow Aventamed to seek regulatory approvals to sell its Solo earplant device in the US, having already launched in European markets.

The fibrosis drug developer has passed a clinical milestone to trigger the final part of a series B round backed by Pfizer, Novartis and Bristol-Myers Squibb.

The genetic testing service took its total funding to about $53m with a round co-led by Alibaba Entrepreneurs Fund and VC fund Beyond Ventures.

The firm, launched with a $100m investment by Illumina in April 2016, has added $130m from unnamed external investors.

Pfizer Venture Investments and Lundbeckfond Ventures have contributed to a fundraise that will support the orphan-drug accelerator's activities through 2021.

The capital will be used to start clinical development of a technique developed at Columbia University that could help tackle heart and metabolic diseases.

Biopharmaceutical developer Fortress Biotech has set up a new subsidiary to develop a treatment for amyloidosis licensed from Columbia University.

Bain Capital Life Sciences, Cormorant Asset Management and RA Capital co-led the Staidson-backed inflammatory disease drug developer's latest round.